Overview

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Status:
Active, not recruiting
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
This phase I trial studies the molecular profile of breast cancer in Ugandan patients with stage IIB-III breast cancer. Creating a molecular profile of breast cancer my help doctors learn more about biological factors associated with breast cancer in Ugandan patients with as well as measure the benefits of locally available diagnostic studies and the possibility of providing treatment via oral medication.
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
Capecitabine
Cyclophosphamide
Methotrexate